Slacker,
Couldn't agree with you more on that. It is obvious that the severe short status indication for which Iplex™ is FDA approved, is NOT the place where the REAL money is going to be made on this fantastic drug! Diabetes, and cancer are FAR larger markets, and where the future for Insmed lies, imo.
A partner with deep pockets could greatly facilitate that circumstance, imo.
News 
Market Data 
Discover 
